オーロラキナーゼB治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Aurora Kinase B - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0505
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:69
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Aurora Kinase B – Pipeline Review, H2 2019
Summary

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Aurora Kinase B – Pipeline Review, H2 2019, outlays comprehensive information on the Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) – Aurora B kinase is a protein that functions in the attachment of the mitotic spindle to the centromere. It is involved in the bipolar attachment of spindle microtubules to kinetochores and is a key regulator for the onset of cytokinesis during mitosis. It is required for central spindle assembly and cleavage furrow formation.

It plays an important role in cytokinesis checkpoint. Phosphorylation of INCENP leads to increased AURKB activity. Other AURKB substrates involved in centromeric functions and mitosis are CENPA, DES/desmin, GPAF, KIF2C, NSUN2, RACGAP1, SEPT1, VIM/vimentin, GSG2/Haspin, and histone H3. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 3, 3 and 1 respectively. Similarly, the universities portfolio in IND/CTA Filed and Preclinical stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Gastric Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Solid Tumor, Hepatocellular Carcinoma, Myelodysplastic Syndrome, Pancreatic Cancer, Renal Cell Carcinoma, Small-Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC), Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Kidney Cancer (Renal Cell Cancer), Liver Cancer, Lung Cancer, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Prostate Cancer, Refractory Acute Myeloid Leukemia and Relapsed Acute Myeloid Leukemia.

Furthermore, this report also reviews key players involved in Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1)
- The report reviews Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) – Overview
Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) – Companies Involved in Therapeutics Development
AbbVie Inc
Advenchen Laboratories LLC
Amgen Inc
AstraZeneca Plc
Chipscreen Biosciences Ltd
Cielo Therapeutics Inc
Merck & Co Inc
Nanjing Tianyi Bioscience Co Ltd
Nanjing Transthera Biosciences Co Ltd
Nemucore Medical Innovations Inc
Synactix Pharmaceuticals Inc
Vichem Chemie Research Ltd
Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) – Drug Profiles
AL-8326 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-900 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APIOEE-9 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-2811 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCT-137690 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CS-2164 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
danusertib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DBPR-114 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ilorasertib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMI-900 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit AURKA and AURKB for Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit AURKB for Acute Myeloid Leukemia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit AURKA and AURKB for Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TT-00420 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TY-011 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) – Dormant Products
Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) – Discontinued Products
Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) – Product Development Milestones
Featured News & Press Releases
Nov 07, 2019: TransThera Biosciences lead product TT-00420 granted Orphan Drug Designation from FDA to treat Cholangiocarcinoma
Sep 28, 2018: TransThera Biosciences Granted IND Approval from FDA to Soon Start Clinical Trials Targeting TNBC
Dec 21, 2017: Sundia Congratulates NHRI for DBPR114 IND Approval in US & Taiwan
May 10, 2016: Data Published in Journal of Controlled Release Demonstrate Flexibility of ACCURINS to Encapsulate a Broad Range of Physically and Chemically Diverse Payloads with High Encapsulation Efficiency and Tunable Release Kinetics
Feb 10, 2016: AZD2811 ACCURINS Data Published in Science Translational Medicine Highlight One of the First Applications of Nanomedicine to Molecularly Targeted Cancer Therapies
Nov 18, 2015: BIND Therapeutics Announces Initiation of Clinical Studies with Accurin AZD2811 in Solid Tumors
Jun 23, 2015: BIND Therapeutics Announces FDA Authorization of First-in-Human Clinical Trial with AstraZeneca’s Aurora B Kinase Inhibitor Accurin AZD2811
Apr 22, 2015: BIND Therapeutics Presents Data Highlighting Ability of Accurin drug candidate AZD2811 to Accumulate in Target Tissue at AACR Annual Meeting 2015
Mar 18, 2015: Data from Abstracts Validating Potential of BIND Therapeutics AZD2811 to be Presented at American Association for Cancer Research Annual Meeting
Mar 05, 2014: BIND Therapeutics to Present Data on Barasertib at the AACR 2014 Annual Meeting
Sep 03, 2012: Chipscreen filed a new IND application on a novel dual-pathway targeted inhibitor Chiauranib to SFDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbbVie Inc, H2 2019
Pipeline by Advenchen Laboratories LLC, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Chipscreen Biosciences Ltd, H2 2019
Pipeline by Cielo Therapeutics Inc, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Nanjing Tianyi Bioscience Co Ltd, H2 2019
Pipeline by Nanjing Transthera Biosciences Co Ltd, H2 2019
Pipeline by Nemucore Medical Innovations Inc, H2 2019
Pipeline by Synactix Pharmaceuticals Inc, H2 2019
Pipeline by Vichem Chemie Research Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Dormant Products, H2 2019 (Contd..4), H2 2019
Dormant Products, H2 2019 (Contd..5), H2 2019
Discontinued Products, H2 2019
Discontinued Products, H2 2019 (Contd..1), H2 2019

【掲載企業】

AbbVie Inc
Advenchen Laboratories LLC
Amgen Inc
AstraZeneca Plc
Chipscreen Biosciences Ltd
Cielo Therapeutics Inc
Merck & Co Inc
Nanjing Tianyi Bioscience Co Ltd
Nanjing Transthera Biosciences Co Ltd
Nemucore Medical Innovations Inc
Synactix Pharmaceuticals Inc
Vichem Chemie Research Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[オーロラキナーゼB治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆